Knockout of STE20-type kinase TAOK3 does not attenuate diet-induced NAFLD development in mice.
Genetic compensation
Non-alcoholic fatty liver disease
Non-alcoholic steatohepatitis
Systemic glucose and insulin homeostasis
TAOK3
Journal
Molecular medicine (Cambridge, Mass.)
ISSN: 1528-3658
Titre abrégé: Mol Med
Pays: England
ID NLM: 9501023
Informations de publication
Date de publication:
20 Oct 2023
20 Oct 2023
Historique:
received:
02
08
2023
accepted:
11
10
2023
medline:
2
11
2023
pubmed:
21
10
2023
entrez:
20
10
2023
Statut:
epublish
Résumé
Non-alcoholic fatty liver disease (NAFLD), the primary hepatic consequence of obesity, is affecting about 25% of the global adult population. The aim of this study was to examine the in vivo role of STE20-type protein kinase TAOK3, which has been previously reported to regulate hepatocellular lipotoxicity in vitro, in the development of NAFLD and systemic insulin resistance in the context of obesity. Taok3 knockout mice and wild-type littermates were challenged with a high-fat diet. Various in vivo tests were performed to characterize the whole-body metabolism. NAFLD progression in the liver, and lipotoxic damage in adipose tissue, kidney, and skeletal muscle were compared between the genotypes by histological assessment, immunofluorescence microscopy, protein and gene expression profiling, and biochemical assays. Intracellular lipid accumulation and oxidative/ER stress were analyzed in cultured human and mouse hepatocytes where TAOK3 was knocked down by small interfering RNA. The expression of TAOK3-related STE20-type kinases was quantified in different organs from high-fat diet-fed Taok3 TAOK3 deficiency had no impact on body weight or composition, food consumption, locomotor activity, or systemic glucose or insulin homeostasis in obese mice. Consistently, Taok3 In contrast to the in vitro observations, genetic deficiency of TAOK3 in mice failed to mitigate the detrimental metabolic consequences of chronic exposure to dietary lipids, which may be partly attributable to the activation of liver-specific compensation response for the genetic loss of TAOK3 by related STE20-type kinases.
Identifiants
pubmed: 37864157
doi: 10.1186/s10020-023-00738-y
pii: 10.1186/s10020-023-00738-y
pmc: PMC10589923
doi:
Substances chimiques
Lipids
0
Tack3 kinase, mouse
EC 2.7.11.1
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
138Informations de copyright
© 2023. The Feinstein Institute for Medical Research.
Références
Diabetologia. 2016 Feb;59(2):341-53
pubmed: 26553096
JCI Insight. 2023 Jan 24;8(2):
pubmed: 36512409
FASEB J. 2015 Apr;29(4):1564-76
pubmed: 25609431
Nat Immunol. 2017 Mar;18(3):313-320
pubmed: 28068307
Gut. 2021 Feb 25;:
pubmed: 33632710
Int J Mol Sci. 2019 Apr 02;20(7):
pubmed: 30986904
Nat Med. 2018 Jul;24(7):908-922
pubmed: 29967350
J Hepatol. 2023 Aug;79(2):538-551
pubmed: 36893854
Methods Enzymol. 2014;537:93-122
pubmed: 24480343
Nat Rev Gastroenterol Hepatol. 2019 Jul;16(7):411-428
pubmed: 31028350
Cell. 2021 May 13;184(10):2537-2564
pubmed: 33989548
Hepatology. 2005 Jun;41(6):1313-21
pubmed: 15915461
Diabetes. 2015 Aug;64(8):2791-804
pubmed: 25845663
JAMA. 2020 Mar 24;323(12):1175-1183
pubmed: 32207804
Nat Metab. 2022 Jan;4(1):60-75
pubmed: 35102341
J Lipid Res. 2022 Jul;63(7):100238
pubmed: 35679904
Front Physiol. 2021 May 07;12:664222
pubmed: 34025452
Mol Cell Endocrinol. 2014 Aug 5;393(1-2):143-51
pubmed: 24976178
Nat Rev Gastroenterol Hepatol. 2021 Feb;18(2):85-86
pubmed: 33420415
Cell Commun Signal. 2020 Oct 21;18(1):164
pubmed: 33087151
Hepatol Commun. 2021 Mar 16;5(7):1183-1200
pubmed: 34278168
J Immunol. 2018 Dec 1;201(11):3431-3442
pubmed: 30373850
FASEB J. 2013 Sep;27(9):3660-71
pubmed: 23729594
Nat Rev Gastroenterol Hepatol. 2023 Aug;20(8):487-503
pubmed: 36932227
J Hepatol. 2021 Dec;75(6):1476-1484
pubmed: 34453963
Mol Metab. 2021 Dec;54:101353
pubmed: 34634521
Nucleic Acids Res. 2006;34(16):4486-94
pubmed: 16945951
J Hepatol. 2023 Feb;78(2):442-447
pubmed: 36216134
Cell Mol Gastroenterol Hepatol. 2019;7(3):597-618
pubmed: 30576769
Dis Model Mech. 2010 Sep-Oct;3(9-10):525-34
pubmed: 20713647
Nat Med. 2023 Mar;29(3):562-573
pubmed: 36894650
FASEB J. 2019 Sep;33(9):9974-9989
pubmed: 31173506
Hepatol Commun. 2023 Mar 17;7(4):
pubmed: 36930872
Hepatol Commun. 2017 Nov 20;2(1):69-83
pubmed: 29404514
Am J Physiol. 1987 Aug;253(2 Pt 1):E179-86
pubmed: 3303966
Diabetologia. 2017 Mar;60(3):553-567
pubmed: 27981357
FASEB J. 2021 May;35(5):e21567
pubmed: 33891332
FASEB J. 2016 Oct;30(10):3628-3643
pubmed: 27421788
J Lipid Res. 2020 Feb;61(2):178-191
pubmed: 31857389
Mol Cancer Ther. 2019 Nov;18(11):2097-2110
pubmed: 31395684
Lancet. 2021 Jun 5;397(10290):2212-2224
pubmed: 33894145
Proc Natl Acad Sci U S A. 2020 Dec 8;117(49):31331-31342
pubmed: 33214146